Current stock page

Financial Data

PACB Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

PACBPacific Biosciences of California, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

BearishEdge 4/10
$1.83+$0.01 (+0.55%)

Latest quote

  • Momentum
    84
  • Value
    23
  • Quality
    32
  • Risk resilience
    24
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$40.56M
+5.5% YoY
Net income
-$37.85M
+0.4% YoY
Free cash flow
-$38.59M
−107.3% YoY
Operating margin
-91.2%
+9.7 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

PACB, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+5.5%$41M$39M$37M$45M$38M$40M$37M$39M
Gross profit−10.6%$13M$13M$13M$17M$15M$15M−$1M$10M
Operating income+4.7%−$37M−$45M−$38M−$41M−$39M−$45M−$429M−$153M
Net income+0.4%−$38M−$45M−$8M−$40M−$38M−$42M−$426M$2M
EPS (diluted)+7.7%−$0.12−$0.14−$0.03−$0.13−$0.13−$0.14−$1.44$0.01
Gross margin−6.0 pts33.2%32.4%34.5%37.5%39.2%36.9%-3.7%25.6%
Operating margin+9.7 pts-91.2%-114.4%-102.0%-92.3%-101.0%-112.8%-1154.5%-390.1%
Net margin+5.6 pts-93.3%-114.7%-22.3%-90.4%-98.9%-105.4%-1146.8%6.0%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−101.0%−$38M−$80M−$45M−$19M−$19M−$29M−$44M−$31M
Capital expenditure−1248.8%−$988K−$2M−$3M−$861K$86K−$550K−$6M−$2M
Free cash flow−107.3%−$39M−$82M−$48M−$20M−$19M−$30M−$50M−$32M
Free cash flow margin−46.7 pts-95.1%-209.8%-128.4%-44.6%-48.4%-75.3%-135.8%-82.3%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets−10.2%$721M$752M$782M$784M$803M$825M$861M$1.26B
Total liabilities+2.0%$782M$785M$780M$779M$767M$764M$769M$754M
Shareholders' equity−270.1%−$61M−$33M$2M$5M$36M$61M$92M$507M
Total debt+0.3%$705M$706M$703M$759M$703M$699M$699M$672M
Cash and equivalents−1.0%$56M$61M$56M$64M$56M$55M$59M$55M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/B ratio——182.2592.0014.846.153.560.75
Return on equity——-54.3%-102.1%-14.0%-8.6%-7.2%-61.2%
Debt to equity——297.29141.9819.4811.377.631.33
Free cash flow yield+5.6 pts-19.0%-47.3%-27.0%-24.2%-24.5%-41.6%-56.1%-55.8%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio-4.33x
P/B ratio-9.23x
Revenue growth (YoY)5.52%
EPS growth (YoY)7.69%
Gross margin34.51%
Operating margin-99.59%
ROE604.22%
ROIC-24.48%
Debt to equity-11.49
FCF yield-33.10%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$1.83
Volume
As of Nov 13, 2026
7.02M
RSI (14)
As of Nov 13, 2026
43.07
MACD
As of Nov 13, 2026
0.02
MACD signal
As of Nov 13, 2026
0.09
MACD histogram
As of Nov 13, 2026
-0.08
ADX (14)
As of Nov 13, 2026
27.37
SMA (50)
As of Nov 13, 2026
$2.00
SMA (200)
As of Nov 13, 2026
$1.60
ATR (14)
As of Nov 13, 2026
$0.28
Historical volatility (annualized)
As of Nov 13, 2026
114.08%
Volume (20-day average)
As of Nov 13, 2026
12.45M
Risk measures
MetricValue
Resilience score24/100
Beta2.1
Annual volatility93.55%
Max drawdown-58.43%
Sharpe ratio0.61
VaR (95%, 1-day)-8.99%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PACB Financial Data FAQ

What is Pacific Biosciences of California, Inc.'s revenue?

Pacific Biosciences of California, Inc.'s revenue is one of the core financial data points for PACB. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Pacific Biosciences of California, Inc.'s revenue growing?

Revenue growth shows whether Pacific Biosciences of California, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PACB's EPS?

PACB's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Pacific Biosciences of California, Inc.'s net income?

Pacific Biosciences of California, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Pacific Biosciences of California, Inc. generate?

Free cash flow shows how much cash Pacific Biosciences of California, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Pacific Biosciences of California, Inc. have?

Cash and debt help frame PACB's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.